Infliximab manufacturers
- Infliximab
-
- $0.00 / 1kg
-
2025-05-14
- CAS:170277-31-3
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 20tons
- Infliximab
-
- $98.00 / 1mg
-
2024-11-18
- CAS:170277-31-3
- Min. Order:
- Purity: 99.70%
- Supply Ability: 10g
- Infliximab USP/EP/BP
-
- $1.10 / 1g
-
2021-07-02
- CAS:170277-31-3
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Infliximab Basic information |
| Product Name: | Infliximab | | Synonyms: | Avakine;Immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal ca2 heavy chain), disulfide with human-mouse monoclonal ca2 light chain, dimer;Remicade;Unii-B72hh48flu;CT-P 13;Infliximab USP/EP/BP;Research Grade Infliximab(DHB94403);TNFR1,Infliximab,anti-inflammatory,Avakine,Tumor Necrosis Factor Receptor,autoimmune,diabetic,TNFR,PTP1B,neuropathy,Inhibitor,TNFR2,monoclonal,TNF Receptor,inhibit,CT-P13 | | CAS: | 170277-31-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Infliximab Structure]() |
| | Infliximab Chemical Properties |
| storage temp. | Store at -30°C | | form | Solid | | color | White to off-white |
| | Infliximab Usage And Synthesis |
| Uses | Infliximab targets the transcription factor NF-κB with harmine and related compounds for treatment of cancers and inflammatory diseases and combination with other agents | | in vivo | A single injection of Infliximab (10 μg/g in 100 μL saline/dose ip) in diabetic TNF-α+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab[2]. |
| | Infliximab Preparation Products And Raw materials |
|